CRABP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL3302926	1.00	1/20
SCHEMBL7715323	0.80	1/20
SCHEMBL7746407	0.76	1/20
SCHEMBL6373022	0.75	1/20
SCHEMBL6872345	0.74	1/20
SCHEMBL7713134	0.74	1/20
SCHEMBL5084210	0.72	1/20
SCHEMBL6880768	0.72	1/20
SCHEMBL7879749	0.72	1/20
SCHEMBL6372002	0.71	1/20
SCHEMBL6881850	0.71	1/20
SCHEMBL6881859	0.70	1/20
SCHEMBL6873444	0.70	1/20
SCHEMBL6881694	0.70	1/20
SCHEMBL8460052	0.70	1/20
SCHEMBL846110	0.69	1/20
SCHEMBL7882967	0.68	1/20
SCHEMBL6378967	0.68	1/20
SCHEMBL6880686	0.68	1/20
SCHEMBL5737254	0.67	1/20

Clinical trials — most relevant to CRABP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Mechanisms of Lipodystrophy in HIV-Infected Pateints	PHASE4	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19	PHASE2	UNKNOWN
Preoperative Bexarotene Treatment for Cushing's Disease	PHASE1/PHASE2	UNKNOWN
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis	PHASE2	UNKNOWN
Daratumumab in Combination With ATRA	PHASE1/PHASE2	COMPLETED
Phase II 5-Azacytidine Plus VPA Plus ATRA	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)	PHASE2	COMPLETED
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	PHASE2	UNKNOWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid	PHASE1	UNKNOWN
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa	PHASE1	COMPLETED
Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers	PHASE1	COMPLETED
Expression and Function of the Renin-Angiotensin System in the Esophagus	EARLY_PHASE1	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia	nan	COMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features	nan	UNKNOWN
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Prevalence Of Vitamin A Deficiency In Critically Ill Children With Sepsis And Its Association With Clinical Outcomes	nan	COMPLETED
The Role of TBX3 in Human ES Cell Differentiation	nan	WITHDRAWN
Biomarkers in Retinitis Pigmentosa	nan	UNKNOWN
Studies on the Expression and Functions of RLIP76 in Blood Samples of Healthy Human Subjects	nan	WITHDRAWN
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes	nan	ACTIVE_NOT_RECRUITING
Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CRABP2 binder may also engage these)

Protein	Name	Similarity
Q5PXY7	—	1.000	Q5PXY7 →
P22935	—	0.998	P22935 →
O42386	—	0.996	O42386 →
P51673	—	0.995	P51673 →
P50568	—	0.994	P50568 →
Q6T499	—	0.984	Q6T499 →
Q5R2J5	—	0.968	Q5R2J5 →
P40220	—	0.964	P40220 →
P29762	—	0.957	P29762 →
P62965	—	0.949	P62965 →
P62964	—	0.948	P62964 →
P62966	—	0.945	P62966 →
Q9EPC5	—	0.941	Q9EPC5 →
A0A0K0MJ13	—	0.937	A0A0K0MJ13 →
Q96R05	—	0.931	Q96R05 →
Q08652	—	0.930	Q08652 →
P50121	—	0.930	P50121 →
FABP5	Fatty acid-binding protein 5	0.925	landscape →
P86412	—	0.923	P86412 →
P06768	—	0.923	P06768 →
P55052	—	0.922	P55052 →
A0A0K0MJN3	—	0.922	A0A0K0MJN3 →
Q99P60	—	0.921	Q99P60 →
FABP4	Fatty acid-binding protein, adipocyte	0.921	landscape →
A0A0K9RL25	—	0.921	A0A0K9RL25 →
Q61316	—	0.921	Q61316 →
Q66RP5	—	0.921	Q66RP5 →
P70623	—	0.921	P70623 →
Q2TFN9	—	0.920	Q2TFN9 →
HSPA4	Heat shock 70 kDa protein 4	0.920	landscape →